US Stock Movement | Hutchmed (HCM.US) rises over 3%, submits NDA to FDA for collaborative therapy of Savolitinib and Osimertinib
On Wednesday, Hutchmed (HCM.US) rose by over 3%, closing at $14.59.
According to Golden Ten Data APP, on Wednesday, HUTCHMED (HCM.US) rose more than 3%, closing at $14.59. In terms of news, on September 29, HUTCHMED announced that AstraZeneca had submitted a new drug application to the US FDA for the combination therapy of Orpathys and Tagrisso. This therapy is intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have MET overexpression or amplification and experienced disease progression during or after EGFR TKI therapy. The global phase III SAFFRON study showed that this combination therapy demonstrated improvements in both progression-free survival and overall survival.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley is tactically bullish on BHP (BHP.US): Two major copper mine catalysts may ignite the stock price in the next two months
Morgan Stanley maintains an "Overweight" rating on BHP Group, with an "attractive" industry outlook, and sets a target price of AUD 69.00 for its shares listed in Australia.
Bank of England hawkish official: Growth exceeds expectations and employment is resilient, which precisely proves that further rate hikes are necessary.
Megan Greene, a policymaker at the Bank of England, stated that the UK's economic growth surpassing expectations and the resilience of the job market indicate that the Bank of England's efforts to curb inflation are still insufficient.
24 Hour Crypto Recap: Here’s What Happened in the Market
Crypto prices
More
